- Home
- HSBC vs NVS Comparison
HSBC vs NVS Comparison
Compare HSBC & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSBC
- NVS
- Stock Information
- Founded
- HSBC 1865
- NVS 1895
- Country
- HSBC United Kingdom
- NVS Switzerland
- Employees
- HSBC N/A
- NVS N/A
- Industry
- HSBC Savings Institutions
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- HSBC Finance
- NVS Health Care
- Exchange
- HSBC Nasdaq
- NVS Nasdaq
- Market Cap
- HSBC 205.9B
- NVS 230.5B
- IPO Year
- HSBC N/A
- NVS 1991
- Fundamental
- Price
- HSBC $61.67
- NVS $120.93
- Analyst Decision
- HSBC Buy
- NVS Hold
- Analyst Count
- HSBC 1
- NVS 6
- Target Price
- HSBC N/A
- NVS $123.67
- AVG Volume (30 Days)
- HSBC 1.5M
- NVS 1.4M
- Earning Date
- HSBC 07-30-2025
- NVS 07-17-2025
- Dividend Yield
- HSBC 5.32%
- NVS 2.15%
- EPS Growth
- HSBC N/A
- NVS N/A
- EPS
- HSBC 1.08
- NVS 6.38
- Revenue
- HSBC $57,994,000,000.00
- NVS $53,222,000,000.00
- Revenue This Year
- HSBC $9.65
- NVS $7.22
- Revenue Next Year
- HSBC $1.20
- NVS $1.94
- P/E Ratio
- HSBC $10.86
- NVS $18.41
- Revenue Growth
- HSBC 2.38
- NVS 11.50
- 52 Week Low
- HSBC $39.42
- NVS $96.06
- 52 Week High
- HSBC $62.87
- NVS $124.83
- Technical
- Relative Strength Index (RSI)
- HSBC 59.20
- NVS 55.08
- Support Level
- HSBC $59.92
- NVS $120.92
- Resistance Level
- HSBC $62.87
- NVS $124.83
- Average True Range (ATR)
- HSBC 0.53
- NVS 1.43
- MACD
- HSBC 0.12
- NVS -0.05
- Stochastic Oscillator
- HSBC 74.63
- NVS 56.32
About HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in around 60 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.